Pharma Mar, S.A.

BME:PHM Rapport sur les actions

Capitalisation boursière : €715.6m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Pharma Mar Gestion

Gestion contrôle des critères 1/4

Le PDG Pharma Mar's est Jose Fernandez Sousa-Faro, nommé en Jan1986, a un mandat de 38.58 ans. détient directement 6.35% des actions de la société, d'une valeur de € 42.78M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 13.5 ans et 2.2 ans.

Informations clés

Jose Fernandez Sousa-Faro

Directeur général

n/a

Rémunération totale

Pourcentage du salaire du PDGn/a
Durée du mandat du directeur général38.6yrs
Propriété du PDG6.4%
Durée moyenne d'occupation des postes de direction13.5yrs
Durée moyenne du mandat des membres du conseil d'administration2.2yrs

Mises à jour récentes de la gestion

Recent updates

Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Jul 28
Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Jun 01
Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65

Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

May 28
Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry

Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 03
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Jan 25
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden

Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

Apr 28
Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate

We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Mar 08
We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability

Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Mar 05
Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Feb 09
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

Oct 27
We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease

An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Sep 27
An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued

Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Jul 15
Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?

Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

May 04
Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%

Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

Apr 11
Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet

There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Mar 16
There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding

Is Pharma Mar (BME:PHM) Using Too Much Debt?

Jan 09
Is Pharma Mar (BME:PHM) Using Too Much Debt?

Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

Sep 08
Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly

News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Aug 03
News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts

Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

May 31
Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock

Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

May 10
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet

Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 08
Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value

Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Jan 14
Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years

Is Pharma Mar (BME:PHM) A Risky Investment?

Nov 19
Is Pharma Mar (BME:PHM) A Risky Investment?

PDG

Jose Fernandez Sousa-Faro

38.6yrs

Titularisation

€294,000

Compensation

Mr. José María Fernández Sousa-Faro, Ph D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000.He serves as the Chief Executive Officer and President of Pharma Mar, S.A.U. He serves as...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Jose Fernandez Sousa-Faro
Founder38.6yrs€294.00k6.35%
€ 45.5m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00kpas de données
Juan Carretero
Founderno datapas de donnéespas de données
María de Francia Caballero
Chief Financial Officer24.6yrspas de donnéespas de données
José Moreno Martinez-Losa
Head of Capital Markets & Investor Relations9.6yrspas de donnéespas de données
Juan Pulido
General Counsel & Secretary of the Board of Directors4.9yrspas de donnéespas de données
Sandra Sanchez
Global Compliance Head4.3yrspas de donnéespas de données
Lara Vadillo
Communication Directorno datapas de donnéespas de données
Belén Veramendi
Director of Corporate Development2.6yrspas de donnéespas de données
Luis Cuenca
Director of Human Resources & IT21.1yrspas de donnéespas de données
Luis Mora Capitan
Managing Director of Oncology & Virology Business Units17.3yrspas de donnéespas de données
Pascal Besman
Chief Operating Officer of Pharmar U.S.no datapas de donnéespas de données

13.5yrs

Durée moyenne de l'emploi

Gestion expérimentée: L'équipe de direction de PHM est chevronnée et expérimentée (ancienneté moyenne 13.5 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Jose Fernandez Sousa-Faro
Founderno data€294.00k6.35%
€ 45.5m
Pedro Fernandez Puentes
Executive Vice-Chairmanno data€124.00kpas de données
Eduardo Serra Rexach
Independent Other External Director3.6yrs€35.00k0.063%
€ 449.3k
M. Solchaga Catalan
Independent Other External Directorno data€35.00kpas de données
Montserrat Andrade Detrell
Proprietary Directorno data€34.00k5.44%
€ 38.9m
Blanca Hernandez Rodriguez
Independent Director5.6yrspas de donnéespas de données
Maria Sandra Mera
Representative Proprietary Director3.7yrspas de donnéespas de données
Rosa Maria Alonso
Independent Director2.2yrspas de données0.0010%
€ 7.5k
Mariano Rodriguez
Independent Coordinating Director2.2yrspas de donnéespas de données
Emiliano Aller
Independent Director2.2yrspas de donnéespas de données
Fernando Santos
Independent Other External Directorno datapas de donnéespas de données
Soledad Miranda
Independent Director1.3yrspas de donnéespas de données

2.2yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Les membres du conseil d'administration de PHM ne sont pas considérés comme expérimentés (ancienneté moyenne 2.2 ans), ce qui suggère un nouveau conseil d'administration.